Ann: Emyria Recruits First Patient MDMA-Assisted Therapy Trial, page-13

Biggest factor as I see it hold SP back is impeding cap raise, funds were low as it was but post pax acquisition you’d have to say it could only be around the corner.

RX5 even if successful was sold off relatively cheap, maybe just enough there to keep the lights on another quarter or two.

but beyond RX5 - what’s the main play now?

RX7 seems very quiet

mdma assisted therapy isn’t going to generate large amounts of revenue.

If they get their own mdma variant through tga then maybe you could say the wheels might finally start turning.

I sold my parcel @ 14c pretty much just got out what I had in, reluctant to jump back in though, will reconsider if it goes sub 10c

all IMO